Access Pharmaceuticals announced that it is evaluating options for the commercialization of MuGard, a mucoadhesive oral wound rinse for managing oral mucositis, in North America. Earlier this year, the company announced that it would release the product in Europe.
A previously announced licensing agreement between Access and Milestone Biosciences for North American rights to MuGard has been terminated, the company said.
Frank Jacobucci, formerly president and CEO of Milestone Biosciences, has joined Access as a consultant, and will assist with ongoing reimbursement, manufacturing, and commercial launch activities at Access, while discussions with potential licensee and copromotion partners are ongoing.
"Access is focused on maximizing the potential of MuGard, both for patients and for its shareholders," said Jeffrey Davis, president and CEO of Access. "Bringing MuGard back in-house will enable Access to capture more of MuGard's value for shareholders, and be more intimately involved in the ongoing commercialization activities."
The market for oral mucositis treatment, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion worldwide, according to Access.
Copyright © 2009 DrBicuspid.com
%20nov12024.q9h8imREpF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20nov12024.q9h8imREpF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
